Choose language:
About us Products Manufacturing Investor Relations Announcements 2008 2007 2006 2005 2004 2003 Annual General Meeting 2008 Share Price Key Figures Financial Calendar Annual & Interim Reports Shareholder Information Investment Calculator Presentations Conference call Analyst Coverage IR Policy Articles of Association Guidelines for Incentive Pay Corporate Governance Contact Media Join Us		Announcements for the Copenhagen Stock Exchange in 2004 17 December 2004 (No. 32-04) Bavarian Nordic A/S Revises Financial Outlook for Year-end 2004 Results 16 December 2004 (No. 31-04) Bavarian Nordic A/S establishes two new operations in the USA and re-starts activities in cancer immunotherapy. 13 December 2004 (No. 30-04) Bavarian Nordic A/S issues Financial Calendar for 2005 24 November 2004 (No. 29-04) Bavarian Nordic A/S announces insiders trading in company shares 4 November 2004 (No. 28-04) Bavarian Nordic A/S announces insiders trading in company shares 3 November 2004 (No. 27-04) Bavarian Nordic awards warrants 26 October 2004 (No. 26-04) Bavarian Nordic A/S – Third Quarterly Report as of 30 September 2004 1 October 2004 (No. 25-04) Bavarian Nordic A/S – Quarterly Statement of Share Ownership 30 September 2004 (No. 24-04) Bavarian Nordic awarded a USD 100 million contract from US Government to further develop IMVAMUNE™ as safe smallpox vaccine 23 September 2004 (No. 23-04) Bavarian Nordic A/S announces insiders trading in company shares 15 September 2004 (No. 22-04) Bavarian Nordic A/S announces insiders trading in company shares 7 September 2004 (No. 21-04) Bavarian Nordic A/S announces insiders trading in company shares 31 August 2004 (No. 20-04) Bavarian Nordic A/S announces insiders trading in company shares 27 August 2004 (No. 19-04) Bavarian Nordic A/S announces insiders trading in company shares 25 August 2004 (No. 18-04) Interim Report as of 30 June, 2004 and other developments in the company 21 July 2004 (No. 17-04) FDA Grants Fast Track Designation for Bavarian Nordic’s Third Generation Smallpox Vaccine Candidate IMVAMUNE™ 19 July 2004 (No. 16-04) US Government Grants Patent to Bavarian Nordic on MVA-BN® 15 July 2004 (No. 15-04) Bavarian Nordic and GlaxoSmithKline Enter into Global Collaboration on IMVAMUNE™ 1 July 2004 (No. 14-04) Bavarian Nordic A/S - Quarterly Statement of Share Ownership 27 May 2004 (No. 13-04) Bavarian Nordic A/S announces insiders trading in company shares 11 May 2004 (No. 12-04) Bavarian Nordic reports positive results from Phase ll dose finding trial with IMVAMUNE™ 10 May 2004 (No. 11-04) Bavarian Nordic A/S announces insiders’ trading in company shares. 6 May 2004 (No. 10-04) Bavarian Nordic A/S announces insiders trading in company shares 5 May 2004 (No. 09-04) US FDA grants IND to Bavarian Nordic, trial with IMVAMUNE™ smallpox vaccine in atopic dermatitis to start 3 May 2004 (No. 08-04) Bavarian Nordic A/S changes its registered office, increases its share capital, and announces insiders trading in company shares 30 April 2004 (No. 07-04) Bavarian Nordic A/S – Report on the results of the Annual Meeting, held 30 April 2004 30 April 2004 (No. 06-04) Bavarian Nordic A/S – First Quarter 2004 Results 15 April 2004 (No. 05-04) Notice convening ordinary general meeting in Bavarian Nordic A/S 5 April 2004 (No. 04-04) Bavarian Nordic A/S – Quarterly Statement of Share ownership 30 March 2004 (No. 03-04) IMVAMUNE™ selected as brand name for Bavarian Nordic’s MVA-BN smallpox vaccine; new vaccine manufacturing facility expected to be operational mid-2005. 4 March 2004 (No. 02-04) Bavarian Nordic A/S – Annual Results 2003 5 January 2004 (No. 01-04) Bavarian Nordic A/S – Quarterly Statement of Share Ownership
Home | Sitemap | Disclaimer | Privacy Contact us